SYSTEMATIC REVIEW article

Front. Med., 23 January 2026

Sec. Obstetrics and Gynecology

Volume 12 - 2025 | https://doi.org/10.3389/fmed.2025.1730505

Heat therapy for primary dysmenorrhea: a systematic review and meta-analysis

  • 1. School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

  • 2. Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

  • 3. School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

Article metrics

View details

1,5k

Views

88

Downloads

Abstract

Aim:

Primary dysmenorrhea is highly prevalent and often suboptimally managed, as non-steroidal anti-inflammatory drugs (NSAIDs) fail to provide analgesia in 18% of women. This review therefore aims to evaluate the efficacy and safety of heat therapy—a widely used self-care method—for both preventing and acutely treating primary dysmenorrhea.

Methods:

We searched seven databases (CENTRAL, PubMed, Web of Science, EMBASE, CNKI, VIP, Wanfang) from inception to October 28, 2024 and updated to August 03, 2025. Pairs of reviewers independently screened records, extracted data, and assessed risk of bias using a modified Cochrane RoB 1.0 tool. Random-effects meta-analyses were performed for pain intensity (converted to 10-cm VAS) and adverse events. Evidence certainty was graded via GRADE (Grading of Recommendations, Assessment, Development, and Evaluations).

Results:

We screened 2,733 citations and included 57 RCTs (involving 5,359 female participants). When compared with no treatment, heat therapy may reduce pain intensity to a greater extent after 3 months (25 RCTs, 2,393 females, WMD −1.85 cm, 95% CI −2.29 to −1.41 cm, RD 21%); it may lead to a greater reduction within 24 h of treatment (3 RCTs, 248 females; WMD −3.52 cm, 95% CI −5.01 to −2.02 cm, RD 45%). When compared to NSAIDs, heat therapy may provide comparable or slightly superior pain relief after 3 months of treatment (22 RCTs, 1,938 females, WMD −1.10 cm, 95% CI −1.51 to −0.70 cm, RD 4%), or within 24 h of treatment (2 RCTs, 167 females, WMD −1.50 cm, 95% CI −2.86 to −0.15 cm, RD 16%). For the safety assessment, heat therapy probably reduced the risk of adverse effects compared with NSAIDs (8 RCTs, 728 females, RR 0.30, 95% CI 0.15–0.59).

Conclusions:

Compared to no treatment, heat therapy is likely to reduce pain intensity both during prophylaxis and acute episodes. When compared to NSAIDs, heat therapy may achieve comparable analgesic efficacy while exhibiting a superior safety profile.

Systematic review registration:

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251050944, identifier CRD420251050944.

1 Introduction

Primary dysmenorrhea is a pervasive yet frequently overlooked public health issue, affecting up to 90% of reproductive-aged women worldwide (1). It is defined as painful menstrual cramps in the absence of pelvic pathology (2). The repercussions are substantial, with severe symptoms leading to activity restriction and absenteeism from work or school in up to 15% of affected women, underscoring its considerable socioeconomic burden (3, 4).

Research indicates that women with dysmenorrhea have elevated levels of prostaglandins, a hormone known to cause crampy abdominal pain. NSAIDs are medications that work by blocking the production of prostaglandins (5). NSAIDs are effective for treating dysmenorrhea, as demonstrated by a meta-analysis of 35 randomized controlled trials (5). However, a review of 51 different clinical trials found that 18% of women reported little to no relief from menstrual pain with NSAIDs (6). And NSAIDs carry a range of adverse effects, primarily affecting the gastrointestinal, renal, and cardiovascular systems (7). Given these limitations, non-pharmacological alternatives are increasingly sought.

A diverse range of non-pharmacological interventions exists, including dietary supplements, transcutaneous electrical nerve stimulation (TENS), acupuncture, and exercise (811). Among these options, thermal therapy stands out by enabling self-care for patients, offering a superior safety profile, and demonstrating high accessibility and public acceptance. The rationale for focusing on heat is 2-fold. First, it aligns with the prostaglandin-based pathophysiology of dysmenorrhea; applied heat increases pelvic blood flow, which may help to dissipate and reduce the concentration of prostaglandins, thereby relieving ischemia and muscle cramps (12). Second, it offers a unique combination of immediate, non-invasive analgesia and an exceptional safety profile, presenting a practical and accessible option for women seeking to avoid medication-related side effects (13). Therefore, we posit that thermal therapy represents a promising and strategic non-pharmacological approach worthy of in-depth study.

2 Methods

2.1 Literature search

An academic librarian systematically designed and executed comprehensive, database-specific search strategies for seven major biomedical databases: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), VIP Database for Chinese Technical Periodicals, and Wanfang Data. Our systematic search encompassed all available records from each database's inception through October 28, 2024 and updated to August 03, 2025, without imposing language or publication status limitations. We also searched the previous systematic reviews and screened the reference lists and the studies included (Supplementary Table 1).

2.2 Study selection

Pairs of reviewers (HZY, LXX, CZY, ZWY) independently screened titles, abstracts, and subsequently, the full texts of potentially eligible articles using standardized, pre-tested forms. The data extraction form was structured around the PICOS framework, covering participant characteristics (Population), detailed descriptions of the interventions and comparators (Intervention/Comparison), study design (Study), outcome measures (Outcome), along with risk of bias assessments and records of adverse effects (see Supplementary File 1).

Disagreements primarily concerned the applicability of the interventions or the certainty of outcome reporting in the full-text articles assessed. All disagreements were referred to the arbitrator (YDN). The arbitrator made the final decision by referring to the predetermined inclusion criteria outlined in the PICOS framework and based on the original article text.

We included trials that met the following criteria: (1) enrolled patients diagnosed with primary dysmenorrhea; (2) randomized participants to receive localized superficial heat therapy, defined as the application of any device or substance (e.g., electric heating pads, adhesive abdominal warmers, far-infrared belts, or moxibustion) aimed at transferring thermal energy continuously to the body, vs. a control (no treatment, placebo, or NSAIDs); (3) evaluated outcomes either in the immediate term (≤24 h) or analgesic effect or over the longer term (≥3 months) for repeated-use efficacy; and (4) reported measures of pain intensity or safety endpoints.

2.3 Data abstraction and risk of bias assessment

Four reviewers (YDN, LYY, HZY, CZY) extracted data from each eligible trial sequentially, ensuring they faced away from each other during the process. We gathered information on study characteristics, including author name, year of publication, study location, funding source, sample size, and length of follow-up, as well as intervention characteristics and all patient-important outcomes.

In cases where a study reported outcomes at multiple time points, we selected the most commonly reported follow-up period among the eligible trials. To account for within-person variability, we abstracted change scores from baseline; end scores were used only when change scores were not available. Additionally, when multiple instruments or questionnaires were employed to measure a common outcome (such as pain), we abstracted data solely for the most frequently used instrument across the eligible studies.

Three reviewers (HZY, LYY, CZY) independently assessed the risk of bias using a modified Cochrane Risk of Bias Tool 1.0 (14, 15). The tool assessed the following domains: random sequence generation; allocation concealment; blinding of study participants, healthcare providers, and outcome assessors; incomplete outcome data (≥20% missing data was considered high risk of bias); and other potential sources of bias. For each item, responses were scored as “definitely or probably yes” (low risk of bias) or “definitely or probably no” (high risk of bias). Disagreements between reviewers were resolved through discussion and, if necessary, by third-party adjudication (see Supplementary Table 2).

2.4 Data synthesis

For dichotomous outcomes, we calculated the relative risk (RR) and its corresponding 95% confidence interval (CI). For continuous outcomes, we calculated the weighted mean difference (WMD) and its corresponding 95%CI after we converted all the pain intensity data to the 10 cm visual analog scale (VAS) for pain (16). 1.5 cm was considered the minimal clinical important difference (MID) of pain intensity (17). We calculated the modeled risk difference (RD) value for comparisons to make the results easier to be understood.

We used a DerSimonian-Laird random effects model for all meta-analyses. Data were analyzed with STATA software version 17 (Stata Corp, College Station, TX, USA).

2.5 Certainty of evidence

We evaluated the certainty of evidence for all outcomes using the GRADE framework (Grading of Recommendations, Assessment, Development, and Evaluations) (18). Evidence from randomized controlled trials (RCTs) is initially rated as high certainty but was subject to downgrading by one or more levels (to moderate, low, or very low) following assessment across five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias—the latter evaluated through visual inspection of funnel plot asymmetry where ≥10 studies contributed to a meta-analysis. We defined it imprecise when 95% CIs of pain intensity contained either half MID (0.75 cm) or 0 cm, and 95% CIs of adverse events included no difference (RR = 1).

3 Results

3.1 Search results and study characteristics

We screened 2,733 citations, identifying 57 eligible trials (1975) involving 5,359 participants (search flow shown in Figure 1). The median of the mean ages reported across the 53 trials (1925, 2747, 4957, 5974) that provided age data was 22.3 years. Among the 44 trials (1924, 27, 28, 3034, 3744, 47, 5055, 5764, 66, 6874) reporting the duration of primary dysmenorrhea, the median of the mean durations was 44 months. Of the studies reporting location, 54 were conducted in Asia (1928, 3044, 4674), two in Europe (29, 75), and one in South America (45). Twenty-eight trials (2426, 2934, 38, 40, 42, 45, 46, 48, 49, 52, 53, 55, 56, 59, 61, 64, 6668, 73, 74) compared heat therapy with a control group [three (26, 29, 45) assessing short-term effects], and 24 trials (2123, 27, 29, 35, 37, 39, 41, 44, 47, 50, 51, 54, 57, 58, 60, 62, 65, 6972, 75) compared heat therapy with NSAIDs [two (29, 60) assessing short-term effects] (see Table 1).

Figure 1

Flowchart depicting the identification and screening process of studies. Records from databases (3424) and citation searching (7) are initially identified. After removing duplicates, 2733 records are screened, excluding 2518. A total of 215 reports are sought for retrieval, with 2 not retrieved. 213 reports are assessed for eligibility, leading to 57 studies included. Exclusion reasons include study design, duplicates, and others. Seven reports from citation searching are assessed, resulting in zero inclusions. Final inclusions for review are 57 studies.

Search flowchart.

Table 1

Study Intervention Control Funding Country Number of participants at baseline, n Length of follow-up, days Mean duration of condition (SD), months Mean age (SD), years
Ma G 2002 (19) Microwave therapy Ibuprofen NR China 120 90 24 (4.23) 19 (2.73)
Zhang SM 2008 (20) TDP & Moxi Indometacin NR China 98 90 46.76(NR) 19.2 (NR)
Liu C 2011 (21) Moxi Ibuprofen NR China 80 90 68.2 (35.69) 21.22 (5.86)
Sun GY 2012 (22) Moxi & Usual care Ibuprofen & Usual care NR China 60 90 60 (NR) 23 (NR)
Lai J 2012 (23) Super Lizer Indometacin NR China 248 90 41.3 (17.02) 17.7 (2.25)
Li P 2012 (24) Moxi Blank NR China 50 90 74.6 (32.09) 21.9 (1.92)
Hou K 2013 (25) Moxi & NSAID NSAID NR China 78 90 NR 25.6(NR)
Li WJ 2013 (26) Moxi Blank NR China 76 20 min NR NR
Wen XR 2013 (27) Moxi Ibuprofen NR China 60 90 73.2 (36.6) 22.3 (2.53)
Zhu L 2013 (28) Moxi & Acupuncture Acupuncture NR China 60 90 72.7 (35.93) 22.3 (2.53)
Potur DC 2014 (29) Hot post NSAID or Blank Government Turkey 252 8h NR 59.62 (1.18)
Jing XX 2015 (30) Moxi & Ibuprofen Ibuprofen NR China 100 90 27 (3.1) 22.2 (2.14)
Qian SH 2015 (31) RDP & Point application theropy Point application therapy NR China 52 90 41.3 (28.74) 21 (3.96)
Ou Y 2015 (32) Moxi & TCM TCM NR China 221 120 36 (NR) 21.2 (NR)
Zhu LH 2015 (33) Moxi Blank Government China 64 90 59.6 (20.25) 20.3 (1.6)
Li Y 2017 (34) Moxi & Usual care Usual care Government China 70 90 25.5 (12.58) 20.3 (1.05)
Yang MX 2017 (35) Moxi Ibuprofen Government China 152 90 NR 23 (2.92)
Hao MM 2017 (36) Moxi Painkiller NR China 80 90 NR 19.7 (NR)
Wang LY 2018 (37) Moxi Ibuprofen NR China 120 90 78.5 (39.76) 22.3 (2.63)
Chen ZH 2018 (38) Moxi & Acupuncture Acupuncture NR China 93 120 27.2 (14.23) 22.8 (3.1)
Li C 2018 (39) Moxi Ibuprofen NR China 72 90 54.7 (41.75) 23 (1.42)
Li XJ 2018 (40) Moxi Blank Government China 155 90 57 (5.39) 20 (0.5)
Song J 2018 (41) Moxi Ibuprofen NR China 60 90 60.1 (27.77) 23.6 (3.44)
Xian SW 2018 (42) Moxi & Acupuncture Acupuncture Government China 64 180 37.9 (32.13) 20.6 (1.42)
Yan LH 2018 (43) Moxi & Ibuprofen Ibuprofen NR China 106 90 5.4 (0.6) 24.7 (4.64)
Chen CX 2018 (44) Moxi & Ibuprofen Ibuprofen Government China 60 120 17.5 (7.05) 20.3 (1.62)
Machado AFP 2019 (45) Thermal therapy & TENS TENS NR Brazil 44 24 h NR 22.6 (4.08)
Wang MJ 2019 (46) Moxi & TCM TCM NR China 60 90 NR 24.4 (NR)
Huang W 2019 (47) Moxi Ibuprofen Government China 100 90 36.8 (22.82) 20.4 (1.6)
Li L 2019 (48) Moxi & Usual care Usual care NR China 150 90 NR NR
Liao BD 2019 (49) Moxi & Needle warming Moxi Needle warming Moxi NR China 120 120 NR 24 (3)
Jiang M 2020 (50) Moxi Ibuprofen Government China 60 90 30.4 (4.42) 22.2 (4.03)
Liu Q 2020 (51) Moxi Ibuprofen Government China 100 90 48.2 (14.42) 26.3 (4.98)
Liu LY 2020 (52) Moxi Blank Government China 144 90 54 (6.8) 20 (0.5)
Sun L 2020 (53) Moxi & TCM TCM NR China 72 90 68 (27.45) 26 (3.75)
Wei MP 2020 (54) Moxi Ibuprofen NR China 102 90 23.4 (7.04) 20.1 (2.34)
Zhou WY 2020 (55) Moxi & TCM TCM NR China 146 90 38.6 (13.01) 26.7 (1.87)
Song H 2021 (56) Moxi & Acupuncture and cupping Acupuncture and cupping NR China 127 90 NR 22.2 (2.88)
Wei XH 2021 (57) Moxi Ibuprofen NR China 80 90 32.9 (13.53) 20.4 (1.83)
Pan WB 2022 (58) Moxi Ibuprofen Government China 99 90 39.5 (18.83) NR
Wang GQ 2022 (59) Moxi & TCM TCM NR China 90 90 23.4 (7.33) 21 (2.62)
Liang H 2022 (60) Electromagnetic wave Ibuprofen NR China 40 30 min 34 (4.73) 19.2 (1.02)
Yang JQ 2022 (61) Moxi & TCM TCM NR China 62 90 86.7 (35.72) 27 (3.04)
Yang YF 2022 (62) Moxi Ibuprofen NR China 60 90 47.6 (5.23) 35 (5.19)
Zhan L 2022 (63) Moxi Ibuprofen NR China 104 90 19.1 (14.58) 23.4 (2.77)
Shen JW 2023 (64) Moxi patch & TCM TCM Government China 60 90 49.2 (22.86) 29.4 (4.14)
Lin SF 2023 (65) TDP & Moxi Indometacin NR China 50 90 NR 18.1 (3.5)
Ma TT 2023 (66) Moxi patch & TCM TCM NR China 90 180 58.8 (39.49) 27.6 (5.32)
Wu JJ 2023 (67) Moxi & Usual care Usual care Government China 76 90 NR 22 (2.48)
Lin WM 2023 (68) Moxi Ibuprofen Government China 120 90 80.8 (38.49) 24.9 (6.05)
Xing BB 2023 (69) Moxi Ibuprofen NR China 66 90 81 (32.28) 25.2 (2.56)
Yu SY 2024 (70) Moxi patch & TCM TCM NR China 88 90 12.5 (3.4) 26.4 (3.26)
Yang SR 2024 (71) Moxi Ibuprofen Government China 120 90 84 (NR) 26.3 (NR)
Xu YY 2024 (72) Moxi Ibuprofen NR China 68 90 142 (77.94) 29.4 (6.49)
Chen Y 2024 (73) Moxi & Acupuncture Acupuncture NR China 64 90 10.1 (8.33) 25.1 (4.02)
Qiu J 2025 (74) Moxi & catgut embedding Catgut embedding Government China 90 90 8.4 (1.74) 23.4 (2.6)
Ceylan D 2025 (75) Thermal therapy Dexketoprofen trometamol Government Turkey 56 90 NR NR

Baseline characteristics of included studies.

Moxi, moxibustion; TCM, traditional Chinese medicine; TDP, Thermal Diffusion Therapy.

3.2 Risk of bias

The risk of bias assessment for the 57 included trials is summarized in Supplementary Table 2. Random sequence generation was adequately reported in 36 trials (63%) (21, 2729, 3135, 3942, 44, 45, 47, 4953, 5558, 60, 62, 6469, 71, 72, 74), suggesting a low risk of selection bias for this domain in these studies. However, allocation concealment was implemented in only 17 trials (30%) (21, 2729, 3135, 3942, 45, 52, 55, 74), potentially compromising 1.5 cm was considered the minimal clinica integrity. Only 3 trials (5%) (45, 52, 74) blinded participants, and 3 (5%) (28, 40, 45) blinded healthcare providers. This high risk of performance bias means that the expectation of receiving a therapeutic intervention (heat) could have influenced participants' reporting of pain relief. Similarly, blinding of outcome assessors and data analysts was reported in only 6 trials (11%) (28, 33, 35, 40, 41, 52), constituting a significant source of detection bias for the subjective outcome of self-reported pain. Importantly, no trials had ≥20% missing data, which minimizes bias from incomplete outcomes and strengthens the robustness of the pooled analysis.

3.3 Heat therapy vs. blank control

3.3.1 Pain analgesia over 3 months

Low-certainty evidence (25 RCTs, 2,393 patients) (24, 25, 3034, 38, 40, 42, 46, 48, 49, 52, 53, 55, 56, 59, 61, 64, 6668, 73, 74) showed that compared with blank intervention, patients with dysmenorrhea who received heat treatment may have experienced more pain relief (WMD −1.85 cm, 95% CI −2.29 to −1.41 cm; the modeled RD 21%, 95% CI 19% to 22%) (see Tables 2, 3; Figure 2).

Table 2

Comparison Outcome Time point Certainty of evidence Result (heat vs. comparator)
Heat vs. blank control Pain relief (VAS, cm) ≥3 months Low Superior to control (WMD −1.85 cm, 95% CI: −2.29 to −1.41)
Pain relief (VAS, cm) ≤24 h Low Superior to control (WMD −3.52 cm, 95% CI: −5.01 to −2.02)
Adverse effects Various Low Little to no difference (RR 1.34, 95% CI: 0.44 to 4.16)
Heat vs. NSAIDs Pain relief (VAS, cm) ≥3 months 24 h Low Similar efficacy (WMD −1.10 cm, 95% CI: −1.51 to −0.70)
Pain relief (VAS, cm) ≤24 h Low Similar efficacy (WMD −1.5 cm, 95% CI: −2.86 to −0.15)
Adverse effects Various Moderate Safer than NSAIDs (RR 0.3, 95% CI: 0.15 to 0.59)

Summary of key findings: heat therapy vs. control/NSAIDs for primary dysmenorrhea.

Table 3

No. of trials (No. of patients) Follow-up, weeks Risk of bias Inconsistency Indirectness Imprecision Publication bias Treatment association (95% CI) Overall quality of evidence
Pain: 0–10 cm VAS for pain (3 months effect); lower is better; MID = 1.5 cm
25 (2,393) Seriousa Not seriousb, I2=95.95% Not serious Not serious Seriousc Achieved at or above MID
Heat 98% Control 77% Low
Modeled RD 21% (19%, 22%)
WMD −1.85 (−2.29, −1.41)
Pain: 0–10 cm VAS for pain (24 h effect); lower is better; MID = 1.5 cm
3 (248) Seriousa Not seriousb, I2 = 89.10% Not serious Seriousd NA Achieved at or above MID Low
Heat 96% Control 51%
Modeled RD 45% (33%, 48%)
WMD −3.52 (−5.01, −2.02)
Adverse effects
7 (784) Seriousa Not serious, I2 = 43.4% Not serious Seriouse NA RR 1.35 (0.44, 4.16) Low

Grade evidence profile of Heat therapy vs. the blank control on primary dysmenorrhea.

NA, not available. aHigh risk of bias in blinding and randomization bHeterogeneity of more than 50%, but all research effects pointed in the same direction and there were only variations in effect sizes cVisual inspection of the funnel plot indicated asymmetry, suggesting a potential risk of bias (see Supplementary Figure 1). dSmall sample size. e95%CI cross the null line.

Figure 2

Forest plot showing the mean differences between treatment and control groups across multiple studies, with corresponding confidence intervals. Individual study results are represented by blue squares, with size indicating weight percentage. The overall effect, shown as a green diamond, indicates a summary effect size of -1.85, with a confidence interval from -2.29 to -1.41. Heterogeneity statistics are provided below the plot, with tau squared, I squared, and H squared values indicating substantial heterogeneity across studies.

Long-term pain relief: heat therapy group vs. blank group.

3.3.2 Pain analgesia within 24 h

Low-certainty evidence (3 RCTs, 248 patients) (26, 29, 45) suggested that compared with blank intervention, patients with dysmenorrhea who received heat treatment experienced more pain relief (WMD −3.52 cm, 95% CI −5.01 to −2.02 cm; the modeled RD 45%, 95% Cl 33% to 48%) (see Tables 2, 3; Figure 3).

Figure 3

Forest plot showing results from three studies comparing treatment and control groups. Each study is represented by a blue square and line, indicating the mean difference with the ninety-five percent confidence interval. A diamond at the bottom represents the overall effect size. Statistical data, including heterogeneity and test statistics, is displayed on the left.

Short-term pain relief: heat therapy group vs. blank group.

3.3.3 Adverse effects

Low-certainty evidence (7 RCTs, 784 patients) (30, 33, 40, 49, 52, 63, 74) indicated little to no difference in adverse effects between heat therapy and blank intervention for primary dysmenorrhea (RR 1.34, 95% Cl 0.44–4.16) (see Tables 2, 3; Figure 4).

Figure 4

Forest plot showing risk ratios and confidence intervals for seven studies: Jing XX 2015, Zhu LH 2015, Li XJ 2018, Liao BD 2019, Liu LY 2020, Zhan L 2022b, and Qiu J 2025. Each study's risk ratio (RR) with 95% confidence interval is depicted by a horizontal line intersected by a box. The overall effect size is a diamond at 1.35, with I-squared at 43.4% and p-value at 0.101, indicating heterogeneity and significance. Weights are adjusted by random effects analysis.

Adverse effects in the heat therapy and bank groups.

3.4 Heat therapy vs. NSAIDs

3.4.1 Pain analgesia over 3 months

Low-certainty evidence (22 RCTs, 1,938 patients) (2123, 27, 35, 37, 39, 41, 44, 47, 50, 51, 54, 57, 58, 62, 65, 6972, 75) suggested that heat therapy and NSAIDs may be comparable in relieving pain, with WMD −1.10 cm (95% CI −1.51 to −0.70 cm), modeled RD 4% (95% CI 3% to 4%) (see Tables 2, 4; Figure 5).

Table 4

No. of trials (No. of patients) Follow-up, weeks Risk of bias Inconsistency Indirectness Imprecision Publication bias Treatment association (95% CI) Overall quality of evidence
Pain: 0–10 cm VAS for pain (long-lasting effect); lower is better; MID = 1.5 cm
22 (1,938) Seriousa Not seriousb, I2 = 91.55% Not serious Not serious Seriousc Achieved at or above MID
Heat 100% Control 96% Low
Modeled RD 4% (3%, 4%)
WMD −1.10 (−1.51, −0.70)
Pain: 0–10 cm VAS for pain (short-lasting effect); lower is better; MID = 1.5 cm
2 (167) Seriousd Not seriouse, I2 = 80.77% Not serious Seriousf NA Achieved at or above MI Low
Heat 93% Control 77%
Modeled RD 16% (2%, 21%)
WMD −1.50 (−2.86, −0.15)
Adverse effects
8 (728) Seriousa Not serious, I2 = 0% Not serious Not serious NA RR 0.30 (0.15, 0.59) Moderate

Grade evidence profile of Heat therapy vs. medication on primary dysmenorrhea.

NA, not available. aHigh risk of bias in blinding and randomization. bHeterogeneity of more than 50%, but all research effects pointed in the same direction and there were only variations in effect sizes. cVisual inspection of the funnel plot indicated asymmetry, suggesting a potential risk of bias (see Supplementary Figure 2). dHigh risk of bias in blinding. eWe downgraded for Imprecision but not for Inconsistency, as we judged the consistent results here would not substantially impact the overall findings. fSmall sample size and 95% CI cross the half of the MID value.

Figure 5

Forest plot showing the results of a meta-analysis. Each study is listed on the left with treatment and control statistics. Blue squares represent effect sizes, with horizontal lines for confidence intervals. A red vertical line indicates no effect. The green diamond at the bottom represents the overall effect size. Mean differences and weights are provided. Heterogeneity statistics include tau-squared equals zero point eight four, I-squared equals ninety-one point fifty-five percent, and H-squared equals eleven point eighty-three. Test of overall effect is minus one point one zero with a ninety-five percent confidence interval of minus one point five one to minus zero point seven zero.

Long-term pain relief: heat therapy group vs. NSAIDs group.

3.4.2 Pain analgesia within 24 h

Low-certainty evidence (2 RCTs, 167 patients) (29, 60) suggested that heat therapy and NSAIDs may show similar efficacy in pain relief, with WMD −1.5 cm (95% CI −2.86 to −0.15 cm), modeled RD 16% (95% CI 2% to 21%) (see Tables 2, 4; Figure 6).

Figure 6

Forest plot comparing two studies on treatment effects, with mean differences and 95% confidence intervals. Liang H 2022 shows a mean difference of -0.81, while Potur DC 2014 shows -2.19. Overall effect is -1.50. Heterogeneity stats include τ² = 0.77 and I² = 80.77%.

Short-term pain relief: heat therapy group vs. NSAIDs group.

3.4.3 Adverse effects

Moderate-certainty evidence (8 RCTs, 728 patients) (19, 20, 27, 28, 36, 43, 47, 63) indicated that heat therapy probably reduced the risk of adverse effects compared with NSAIDs in primary dysmenorrhea (RR 0.3, 95% Cl 0.15 to 0.59) (see Tables 2, 4; Figure 7).

Figure 7

Forest plot showing relative risk (RR) with 95% confidence intervals for multiple studies. Studies are listed on the left with corresponding RR values and weights on the right. A diamond at the bottom represents the overall effect estimate with RR of 0.30 and 95% confidence interval of 0.15 to 0.59. Vertical line at RR equals 1 indicates no effect. Weights are from random effects analysis.

Adverse effects in the Heat therapy and NSAIDs groups.

4 Discussion

4.1 Overall findings

Compared to no treatment, heat therapy reduces pain in primary dysmenorrhea with comparable safety. When compared to NSAIDs, heat therapy demonstrates minimal difference in pain intensity but is probably associated with fewer adverse events. These treatment outcomes remain consistent across both short-term (24-h) and long-term (3-month) assessments.

4.2 Relation to other studies

We have identified two systematic reviews in the literature addressing heat therapy for primary dysmenorrhea (76, 77); however, we excluded 6 RCTs for specific reasons. The first meta-analysis (76) included three RCTs on thermotherapy. One trial was excluded due to a lack of baseline data (78). The other two (79, 80), with treatment durations of 1 and 2 months, were also excluded. The second meta-analysis (77) included six RCTs (29, 78, 8083), only one of which was included in our analysis (29). The other five trials were excluded due to the absence of extractable outcome measures (78, 80, 81), unavailable resources (82), or non-compliant interventions (83). A detailed breakdown is provided in Supplementary Table 3.

Earlier systematic reviews offered valuable preliminary insights by suggesting heat therapy might be effective and potentially comparable to analgesic medication. However, their conclusions were notably constrained: Jo and Lee's analysis, while indicating superiority over placebo, was limited to only 6 RCTs (77); Igwea et al. identified merely 3 heat therapy trials, were unable to perform a direct comparative meta-analysis, and ultimately highlighted the need for more robust evidence (76).

Our study comprehensively addresses these limitations through key advancements: a markedly expanded evidence base (57 RCTs) enabling more precise and generalizable treatment estimates; broader intervention diversity encompassing microwave therapy, electromagnetic wave therapy, moxibustion, and hot packs beyond previous narrow focus; and demonstration of consistent therapeutic benefits across both immediate (24-h) and sustained (3-month) timeframes—a previously unexamined dimension. Methodologically, the systematic application of the GRADE framework provides rigorous evidence certainty assessment, thereby substantiating prior hypotheses and establishing a more reliable foundation for positioning heat therapy as a viable non-pharmacological treatment for primary dysmenorrhea.

4.3 Strengths and limitations

This review has several strengths. We predefined the MIDs to visually demonstrate between-group differences and evaluate the clinical significance of the findings. The calculation of MID-derived risk differences (RDs) further enhanced the interpretation of the clinical feasibility of treatment effects. Moreover, our study overcomes the limitations of previous analyses by comprehensively incorporating diverse thermotherapy modalities and leveraging a robust sample size, thereby yielding more precise and generalizable estimates.

Nevertheless, several limitations warrant consideration. The methodological quality of many included trials was compromised by inadequate randomization and concealment of allocation. Furthermore, significant heterogeneity was observed in some analyses, likely stemming from clinical diversity in patient populations and variations in heat therapy protocols. Finally, the predominance of studies conducted in Asian populations may limit the generalizability of our findings to other regions.

4.4 Implications

Our findings provide evidence for informing a stepped-care approach to managing primary dysmenorrhea. During acute episodes, local heat therapy using modalities such as hot water bottles or self-heating patches can provide immediate pain relief comparable to NSAIDs, with a superior safety profile. This offers an ideal first-line option for patients who cannot or prefer not to use medication. During the intermenstrual period, regular application of heat therapies like moxibustion or infrared therapy can serve as an effective preventive measure. Long-term adherence may reduce the frequency and intensity of pain episodes and decrease reliance on analgesic medications. For patients with severe pain, a “heat therapy-first, medication-as-supplement” combination strategy could be considered—employing heat therapy both preventively and during acute phases, reserving short-term NSAID use only for peak pain levels to optimize both efficacy and safety.

From a research perspective, the application of MIDs in our meta-analysis offers a concrete method for evaluating the clinical significance of future findings. However, the promising results are constrained by the low certainty of evidence and prevalent risk of bias in existing studies.

Future research should therefore prioritize high-quality, adequately powered RCTs that are specifically designed to overcome these limitations. We recommend that future trials: (1) calculate sample sizes based on the established MIDs for pain scales to ensure sufficient statistical power; (2) predefine and consistently apply a standardized heat intervention protocol (specifying temperature, application site, duration, and treatment frequency) to reduce heterogeneity; (3) adhere to the CONSORT reporting guidelines, providing clear descriptions of randomization, allocation concealment, and blinding methods; and (4) systematically record and report all adverse events to better establish the long-term safety profile of repeated heat application. Such rigorously generated evidence is crucial to confirm these findings and establish clear, evidence-based clinical guidelines.

5 Conclusion

Compared to no treatment, heat therapy is likely to reduce pain intensity both during prophylaxis and acute episodes. When compared to NSAIDs, heat therapy may achieve comparable analgesic efficacy with a superior safety profile.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

DY: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Software, Writing – original draft, Writing – review & editing. YL: Data curation, Formal analysis, Validation, Visualization, Writing – original draft. ZC: Data curation, Investigation, Resources, Supervision, Writing – review & editing. ZH: Formal analysis, Methodology, Software, Validation, Writing – review & editing. XL: Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing. WZ: Investigation, Software, Visualization, Writing – review & editing. KM: Investigation, Visualization, Writing – review & editing. WM: Investigation, Methodology, Writing – review & editing. LL: Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This study was funded by the Chengdu University of Traditional Chinese Medicine University-Institute Joint Innovation Fund (Grant No. LH202402049) and Sichuan provincial project (Grant No. 2022YFS0401).

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2025.1730505/full#supplementary-material

References

  • 1.

    Iacovides S Avidon I Baker FC . What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. (2015) 21:76278. doi: 10.1093/humupd/dmv039

  • 2.

    Ferries-Rowe E Corey E Archer JS . Primary dysmenorrhea: diagnosis and therapy. Obstet Gynecol. (2020) 136:104758. doi: 10.1097/AOG.0000000000004096

  • 3.

    Dawood MY . Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. (2006) 108:42841. doi: 10.1097/01.AOG.0000230214.26638.0c

  • 4.

    Ju H Jones M Mishra G . The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. (2014) 36:10413. doi: 10.1093/epirev/mxt009

  • 5.

    Marjoribanks J Ayeleke RO Farquhar C Proctor M . Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. (2015) 2015:Cd001751. doi: 10.1002/14651858.CD001751.pub3

  • 6.

    Owen PR . Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol. (1984) 148:96103. doi: 10.1016/S0002-9378(84)80039-3

  • 7.

    Essex MN Zhang RY Berger MF Upadhyay S Park PW . Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. Expert Opin Drug Saf. (2013) 12:46577. doi: 10.1517/14740338.2013.780595

  • 8.

    Xu T Hui L Juan YL Min SG Hua WT . Effects of moxibustion or acupoint therapy for the treatment of primary dysmenorrhea: a meta-analysis. Altern Ther Health Med. (2014) 20:3342.

  • 9.

    Abaraogu UO Igwe SE Tabansi-Ochiogu CS Duru DO . A systematic review and meta-analysis of the efficacy of manipulative therapy in women with primary dysmenorrhea. Explore (NY). (2017) 13:38692. doi: 10.1016/j.explore.2017.08.001

  • 10.

    Elboim-Gabyzon M Kalichman L . Transcutaneous electrical nerve stimulation (TENS) for primary dysmenorrhea: an overview. Int J Womens Health. (2020) 12:110. doi: 10.2147/IJWH.S220523

  • 11.

    López-Liria R Torres-Álamo L Vega-Ramírez FA García-Luengo AV Aguilar-Parra JM Trigueros-Ramos R et al . Efficacy of physiotherapy treatment in primary dysmenorrhea: a systematic review and meta-analysis. Int J Environ Res Public Health. (2021) 18:7832. doi: 10.3390/ijerph18157832

  • 12.

    Putney DJ Malayer JR Gross TS Thatcher WW Hansen PJ Drost M . Heat stress-induced alterations in the synthesis and secretion of proteins and prostaglandins by cultured bovine conceptuses and uterine endometrium. Biol Reprod. (1988) 39:71728. doi: 10.1095/biolreprod39.3.717

  • 13.

    Tao XG Bernacki EJ A . randomized clinical trial of continuous low-level heat therapy for acute muscular low back pain in the workplace. J Occup Environ Med. (2005) 47:1298306. doi: 10.1097/01.jom.0000184877.01691.a3

  • 14.

    Higgins JP Altman DG Gøtzsche PC Jüni P Moher D Oxman AD et al . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. (2011) 343:d5928. doi: 10.1136/bmj.d5928

  • 15.

    Akl EA Sun X Busse JW Johnston BC Briel M Mulla S et al . Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol. (2012) 65:2627. doi: 10.1016/j.jclinepi.2011.04.015

  • 16.

    Thorlund K Walter SD Johnston BC Furukawa TA Guyatt GH . Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability. Res Synth Methods. (2011) 2:188203. doi: 10.1002/jrsm.46

  • 17.

    Wang Y Devji T Carrasco-Labra A King MT Terluin B Terwee CB et al . A step-by-step approach for selecting an optimal minimal important difference. Bmj. (2023) 381:e073822. doi: 10.1136/bmj-2022-073822

  • 18.

    Santesso N Glenton C Dahm P Garner P Akl EA Alper B et al . GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. (2020) 119:12635. doi: 10.1016/j.jclinepi.2019.10.014

  • 19.

    Ma Gang TY . Microwave therapy for 60 cases of primary dysmenorrhea. J Guangxi Med Univ. (2002) 2002:6801. doi: 10.16190/j.cnki.45-1211/r.2002.05.036

  • 20.

    Siming Z Yuansheng N Baozhu Q Jinshu H Ruinong Z . A study on the nursing of primary dysmenorrhea with TDP combined with moxibustion. Bright Trad Chin Med. (2008) 2008:1023. doi: 10.3969/j.issn.1003-8914.2008.01.080

  • 21.

    Cheng L Haiyan Z . Therapeutic effect of moxibustion on primary dysmenorrhea due to damp-cold retention. World J Acupunct-Moxibust. (2011) 21:14.

  • 22.

    Guoyao S . Clinical efficacy of moxibustion box warm moxibustion in the treatment of primary dysmenorrhea. Inner Mongolia J Trad Chin Med. (2012) 31:256. doi: 10.16040/j.cnki.cn15-1101.2012.20.036

  • 23.

    Jian L Juan L . Clinical research on the treatment of primary dysmenorrhea with super laser. Clin Med Eng. (2012) 19:6824. doi: 10.3969/j.issn.1674-4659.2012.05.0682

  • 24.

    Pei L Sanqing Z Yuan L Feng J Sensen L . The effect of moxibustion at different time points on primary dysmenorrhea. J Fujian Univ Trad Chin Med. (2012) 22:13. doi: 10.3969/j.issn.1004-5627.2012.05.001

  • 25.

    Ke H . A preliminary study on the treatment of cold-type dysmenorrhea with acupuncture. Everyone's Health (Acad Ed). (2013) 7:171.

  • 26.

    Weijiang L Andi W Xiaowen C Jie C Chen Z . Study on the abdominal infrared thermal imaging characteristics of patients with primary dysmenorrhea treated by acupuncture at dihou point. Shanghai J Acupunct. (2012) 31:65961.

  • 27.

    Xinru W . Clinical study on the treatment of primary dysmenorrhea with acupuncture. J Chengdu Univ Trad Chin Med. (2013).

  • 28.

    Lan Z . Clinical analysis of 35 cases treated with acupuncture and moxibustion for dysmenorrhea. Chin Med J. (2013) 48:989. doi: 10.3969/j.issn.1008-1070.2013.07.045

  • 29.

    Potur DC Kömürcü N . The effects of local low-dose heat application on dysmenorrhea. J Pediatr Adolesc Gynecol. (2014) 27:21621. doi: 10.1016/j.jpag.2013.11.003

  • 30.

    Xinxin J Hang L Hang Y . The efficacy and nursing measures of moxibustion in the treatment of primary dysmenorrhea. Biotechnol World. (2015) 2015:138+40.

  • 31.

    Shanhai Q Lifang T Yin Z Ting J . Observation on the therapeutic effect of three-heat plaster combined with TDP irradiation in the treatment of cold-dampness stagnation type primary dysmenorrhea. Shanghai J Acupunct. (2015) 34:10679. doi: 10.13460/j.issn.1005-0957.2015.11.1067

  • 32.

    Yan O . The effect of moxibustion combined with Taohong Sibu Decoction on serum ET-1 and NO levels in patients with dysmenorrhea. J Changchun Univ Trad Chin Med. (2015) 31:5824. doi: 10.13463/j.cnki.cczyy.2015.03.053

  • 33.

    Lihua Z . A randomized controlled study on the therapeutic effect of scheduled acupuncture for primary dysmenorrhea. J Chengdu Univ Trad Chin Med. (2015).

  • 34.

    Yan L Jing Z Yuwen Y Na L Zhenzhen Z . The effect of moxibustion on the symptoms of primary dysmenorrhea and sleep quality. J Mudanjiang Med Univ. (2017) 38:1436. doi: 10.13799/j.cnki.mdjyxyxb.2017.03.052

  • 35.

    Yang M Chen X Bo L Lao L Chen J Yu S et al . Moxibustion for pain relief in patients with primary dysmenorrhea: a randomized controlled trial. PLoS ONE. (2017) 12:e0170952. doi: 10.1371/journal.pone.0170952

  • 36.

    Meimei H . Observation on the efficacy of moxibustion with moxa sticks in treating dysmenorrhea caused by cold-dampness stagnation. Chin Med Modern Dist Educ China. (2017) 15:1089. doi: 10.3969/j.issn.1672-2779.2017.11.047

  • 37.

    Lingyan W Hongpei C . Clinical observation on 60 cases of primary dysmenorrhea treated with grain-impregnated moxibustion. N Trad Chin Med. (2018) 50:1746. doi: 10.13457/j.cnki.jncm.2018.07.052

  • 38.

    Zhihui C . A randomized parallel controlled study on the treatment of primary dysmenorrhea with acupuncture combined with needling. Pract J Trad Chin Intern Med. (2018) 32:557. doi: 10.13729/j.issn.1671-7813.Z20170114

  • 39.

    Cheng l Xinjian M Xiaoli W . Clinical study on the treatment of primary dysmenorrhea of the cold-damp accumulation type by moxibustion. J Acupunct Clin Pract. (2018) 34:4851. doi: 10.3969/j.issn.1005-0779.2018.06.015

  • 40.

    Xiaoji L . A randomized controlled trial of time-based acupuncture for elective treatment of primary dysmenorrhea based on the theory of time acupuncture. J Chengdu Univ Trad Chin Med. (2018).

  • 41.

    Juan S . Clinical study on the treatment of primary dysmenorrhea of cold-dampness stagnation type by moxibustion combined with “Ziwu flowchart of nailing the heavenly stems method”. J Chengdu Univ Trad Chin Med. (2018).

  • 42.

    Shuwen X Xinyan Z Chunhui L Xianying L . Observation on the therapeutic effect of silver needles combined with moxibustion in treating primary dysmenorrhea in female college students. Matern Child Health Care China. (2018) 33:28179. doi: 10.7620/zgfybj.j.issn.1001-4411.2018.12.61

  • 43.

    Lianhua Y Ting L . Observation on the therapeutic effect of warm moxibustion with moxibustion box on primary dysmenorrhea. Essent Read Health. (2018) 2018:1878.

  • 44.

    Chunxia C Chen W Cong D Wei X Meizhen Z . Clinical research on the treatment of primary dysmenorrhea of cold coagulation syndrome with moxibustion. Popul Technol. (2018) 20:6871. doi: 10.3969/j.issn.1008-1151.2018.08.024

  • 45.

    Machado AFP Perracini MR Rampazo É P Driusso P Liebano RE . Effects of thermotherapy and transcutaneous electrical nerve stimulation on patients with primary dysmenorrhea: a randomized, placebo-controlled, double-blind clinical trial. Complement Ther Med. (2019) 47:102188. doi: 10.1016/j.ctim.2019.08.022

  • 46.

    Meijuan W Juncheng D . Observation on the clinical efficacy of danggui sini decoction combined with heat-sensitive acupuncture in the treatment of primary dysmenorrhea. Jiangxi Trad Chin Med. (2019) 50:578.

  • 47.

    Wei H . Analysis of the therapeutic effect of moxibustion on primary dysmenorrhea in female college students. Healthc Wellness Guide. (2019) 2019:345. doi: 10.3969/j.issn.1006-6845.2019.08.329

  • 48.

    Ling L Guojuan S Xueli S Yalan W Zhi L Ping X . Observation on the therapeutic effect of acupuncture moxibustion combined with steam therapy in the treatment of primary dysmenorrhea (cold stagnation and blood stasis syndrome) in 150 cases. J Sichuan Trad Chin Med. (2019) 37:2102.

  • 49.

    Bodan L Yuane L Zhimou P Chang Z Chao L Jingjing H et al . Observation on the therapeutic effect of acupoint moxibustion at shangwan combined with warm needling at guanyuan and sanyinjiao for the treatment of primary dysmenorrhea. Chin Acupunct Moxibust. (2019) 39:367–70+76. doi: 10.13703/j.0255-2930.2019.04.006

  • 50.

    Mei J Liping D Qingxia L Xiuwu H Chenying D . A controlled study on the intervention of long-needle moxibustion for primary dysmenorrhea of the cold-coagulation and blood-stasis type. Jiangxi Med. (2020) 55:568–70+611. doi: 10.3969/j.issn.1006-2238.2020.05.025

  • 51.

    Qian L Yonghong L Yuting L Muying Z Haini Z Jie Q et al . clinical observation on the treatment of cold-induced primary dysmenorrhea with angelica sinensis and ginger lamb soup. Chin Folk Med. (2020) 28:659. doi: 10.19621/j.cnki.11-3555/r.2020.2426

  • 52.

    Liu LY Li XJ Wei W Guo XL Zhu LH Gao FF et al . Moxibustion for patients with primary dysmenorrhea at different intervention time points: a randomized controlled trial. J Pain Res. (2020) 13:265362. doi: 10.2147/JPR.S270698

  • 53.

    Lian S . Clinical observation on the treatment of primary dysmenorrhea of cold-obstructed blood stasis type with Xiaodui Zhuyu decoction combined with acupuncture therapy. J Shanxi Univ Chin Med. (2020). 2020. doi: 10.27820/d.cnki.gszxy.2020.000165

  • 54.

    Meipan W Tingting A Shanyan Q Meiwu W . Analysis of the effect of acupuncture therapy on primary dysmenorrhea. Contemp Med J. (2020) 18:2045. doi: 10.3969/j.issn.2095-7629.2020.09.150

  • 55.

    Wenya Z Yanmei Z Lezhang Z A . randomized controlled study on the treatment of dysmenorrhea of the cold-stagnation and blood-stasis type with Jinling Sishui Powder combined with Wenzheng acupuncture. Pract Gynecol Endocrinol Electr J. (2020) 7:4950. doi: 10.16484/j.cnki.issn2095-8803.2020.09.030

  • 56.

    Hong S . TDP combined with acupuncture and cupping therapy for the treatment of 127 cases of primary dysmenorrhea in college students. Health Focus. (2021) 2021:140.

  • 57.

    Xiaohan W Shuo Q . Comparison of the effects of moxibustion and Western medicine in treating cold-type dysmenorrhea and their respective advantages. Healthc Wellness Guide. (2021) 2021:289.

  • 58.

    Weibin P Xiaomin L Qiumei C Nan L Yuqiong W . Efficacy of dual-sided thermal stimulation at lumbosacral and abdominal regions for primary dysmenorrhea with cold coagulation and blood stasis pattern in female university students. J Shanxi Univ Chin Med. (2022) 23:56770. doi: 10.19763/j.cnki.2096-7403.2022.06.12

  • 59.

    Guoqin W Yueping S Shanshan C . Therapeutic effects of moxibustion combined with taohong siwu decoction on dysmenorrhea: a clinical analysis. Health Friend. (2022) 2022:1423.

  • 60.

    Hui L Yun X . Analysis of the effect of specific electromagnetic wave therapy devices on primary dysmenorrhea. Chin Sci J Database (Citat Ed): Med Health Sci. (2022) 39:3457. doi: 10.3969/j.issn.1000-7369.2018.03.023

  • 61.

    Jieqiong Y Ying L . Clinical efficacy of dysmenorrhea formula combined with moxibustion for treating primary dysmenorrhea with cold coagulation and blood stasis pattern. Health Essent. (2022) 2022:278.

  • 62.

    Yifan Y Furong Z . Therapeutic efficacy of gynecological-specific moxibustion for primary dysmenorrhea with cold-dampness congelation pattern. Adv Clin Med. (2022) 12:47782. doi: 10.12677/ACM.2022.121070

  • 63.

    Liang Z . Therapeutic impact of intensive moxibustion at baliao points on moderate-to-severe primary dysmenorrhea with cold-dampness congelation pattern. Pract Clin J Integr Trad Chin West Med. (2022) 22:1079. doi: 10.13638/j.issn.1671-4040.2022.01.036

  • 64.

    Jiewen S Wenrong X Feiyun G . Clinical efficacy of modified Shao-Fu-Zhu-Yu decoction combined with governor vessel moxibustion patch for primary dysmenorrhea with cold coagulation and blood stasis pattern. J Women Childrens Health Guide. (2023) 2:31–3+49. doi: 10.3969/j.issn.2097-115X.2023.3.whbb202303010

  • 65.

    Shaofen L . The application of specific electromagnetic spectrum combined with moxibustion in primary dysmenorrhea. J Pract Gynecol Endocrinol. (2023) 10:902. doi: 10.3969/j.issn.2095-8803.2023.18.028

  • 66.

    Tingting M Yanzheng L . Therapeutic analysis of empirical dysmenorrhea decoction combined with moxibustion for dysmenorrhea with cold coagulation and blood stasis pattern. Chin Health Care. (2023) 41:3740.

  • 67.

    Jiaojiao W Jiangyan X Lingli R Xiaoyi Z Shan L Longtao K et al . Nursing intervention of auricular acupoint pressing with seeds combined with portable moxibustion for primary dysmenorrhea in female university students. J Modern Med Health. (2023) 39:87981. doi: 10.3969/j.issn.1009-5519.2023.05.032

  • 68.

    Wenmin L Jisheng W . Clinical study on grain-sized moxibustion for primary dysmenorrhea with cold-dampness congelation pattern. Guangming J Chin Med. (2023) 38:21379. doi: 10.3969/j.issn.1003-8914.2023.11.031

  • 69.

    Bianbian X . Clinical efficacy of heat-sensitive moxibustion for primary dysmenorrhea with cold coagulation and blood stasis pattern (2023). doi: 10.27282/d.cnki.gsdzu.2023.000195

  • 70.

    Shuying Y Li Z . Therapeutic effects of bottle gourd moxibustion for primary dysmenorrhea with cold coagulation and blood stasis pattern. Weekly Digest: Senior Care Weekly. (2024) 2024:1168.

  • 71.

    Songran Y Yan X Yu S Shoubo Y Kaidi G Yalin L . Therapeutic efficacy of bian stone-mediated moxibustion for primary dysmenorrhea. J Women Childrens Health Guide. (2024) 3:269. doi: 10.3969/j.issn.2097-115X.whbb202410008

  • 72.

    Yaoyao X Li G Yiya Y . Clinical efficacy of Bagua-style umbilical-region moxibustion for primary dysmenorrhea with cold coagulation and blood stasis pattern. Res Integr Trad Chin West Med. (2024) 16:702. doi: 10.3969/j.issn.1674-4616.2024.01.019

  • 73.

    Yao C . Chrono-acupuncture combined with heat-sensitive moxibustion for primary dysmenorrhea: a clinical case series of 32 patients. Chin Med. (2024) 13:1738. doi: 10.12677/TCM.2024.131027

  • 74.

    Jing Q Zheng H Ping Y Zhaohua X . Clinical study on heat-sensitive moxibustion combined with acupoint catgut embedding for treating dysmenorrhea due to cold coagulation and blood stasis. Capit Med. (2025) 32:14851. doi: 10.3969/j.issn.1005-8257.2025.09.051

  • 75.

    Ceylan D Başer M . The effect of hot application with cherry seed belt on dysmenorrhoea: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. (2025) 311:114027. doi: 10.1016/j.ejogrb.2025.114027

  • 76.

    Igwea SE Tabansi-Ochuogu CS Abaraogu UO . TENS and heat therapy for pain relief and quality of life improvement in individuals with primary dysmenorrhea: a systematic review. Complement Ther Clin Pract. (2016) 24:8691. doi: 10.1016/j.ctcp.2016.05.001

  • 77.

    Jo J Lee SH . Heat therapy for primary dysmenorrhea: a systematic review and meta-analysis of its effects on pain relief and quality of life. Sci Rep. (2018) 8:16252. doi: 10.1038/s41598-018-34303-z

  • 78.

    Navvabi Rigi S Kermansaravi F Navidian A Safabakhsh L Safarzadeh A Khazaeian S et al . Comparing the analgesic effect of heat patch containing iron chip and ibuprofen for primary dysmenorrhea: a randomized controlled trial. BMC Women's Health. (2012) 12:25. doi: 10.1186/1472-6874-12-25

  • 79.

    Kim JI . Effect of heated red bean pillow application for college women with dysmenorrhea. Korean J Women Health Nurs. (2013) 19:6774. doi: 10.4069/kjwhn.2013.19.2.67

  • 80.

    Ke YM Ou MC Ho CK Lin YS Liu HY Chang WA . Effects of somatothermal far-infrared ray on primary dysmenorrhea: a pilot study. Evid-Based Complement Altern Med. (2012) 2012:240314. doi: 10.1155/2012/240314

  • 81.

    Akin MD Weingand KW Hengehold DA Goodale MB Hinkle RT Smith RP . Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol. (2001) 97:3439. doi: 10.1097/00006250-200103000-00004

  • 82.

    Akin M Price W Rodriguez G Jr Erasala G Hurley G Smith RP . Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. J Reprod Med. (2004) 49:73945.

  • 83.

    Lee CH Roh JW Lim CY Hong JH Lee JK Min EG et al . multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of a far infrared-emitting sericite belt in patients with primary dysmenorrhea. Complement Ther Med. (2011) 19:18793. doi: 10.1016/j.ctim.2011.06.004

Summary

Keywords

primary dysmenorrhea, heat therapy, pain, NSAIDs, meta-analysis

Citation

Yuan D, Liu Y, Chen Z, Hu Z, Li X, Zhang W, Mao K, Ma W and Lan L (2026) Heat therapy for primary dysmenorrhea: a systematic review and meta-analysis. Front. Med. 12:1730505. doi: 10.3389/fmed.2025.1730505

Received

22 October 2025

Revised

15 November 2025

Accepted

12 December 2025

Published

23 January 2026

Volume

12 - 2025

Edited by

Pranay Wal, Pranveer Singh Institute of Technology, Pharmacy, India

Reviewed by

Hanish Singh Jayasingh Chellammal, Universiti Teknologi MARA, Malaysia

Manish Bhise, Sant Gadge Baba Amravati University, India

Updates

Copyright

*Correspondence: Lei Lan,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics